Paclitaxel Therapeutic Drug Monitoring in Cancer Patients
Public ClinicalTrials.gov record NCT03987555. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Pilot Feasibility Study of Paclitaxel Therapeutic Drug Monitoring in Cancer Patients
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The goals of this prospective, observational cohort study are to determine the feasibility of implementing paclitaxel therapeutic drug monitoring for cancer patients and explore the relationship between paclitaxel drug exposure and the development of neuropathic symptoms. This trial studies if paclitaxel can be consistently measured in the blood of patients with solid tumors undergoing paclitaxel treatment. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Nerve damage is one of the most common and severe side effects of paclitaxel. The ability to consistently measure paclitaxel in the blood may allow doctors to control the dose of paclitaxel, so that enough chemotherapy is given to kill the cancer, but the side effect of nerve damage is reduced.
Study identification
- NCT ID
- NCT03987555
- Recruitment status
- Suspended
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 55 participants
Conditions and interventions
Conditions
- Solid Tumor, Adult
- Metastatic Nonsmall Cell Lung Cancer
- Anatomic Stage IV Breast Cancer AJCC v8
- Metastatic Cervical Carcinoma
- Metastatic Ovarian Carcinoma
- Malignant Uterine Neoplasm
- Vulvar Cancer
- Invasive Breast Cancer
- Metastatic Breast Carcinoma
- Prognostic Stage IV Breast Cancer AJCC v8
- Recurrent Breast Carcinoma
- Recurrent Cervical Carcinoma
- Recurrent Lung Non-Small Cell Carcinoma
- Recurrent Ovarian Carcinoma
- Recurrent Vulvar Carcinoma
- Stage IV Cervical Cancer AJCC v8
- Stage IV Lung Cancer AJCC v8
- Stage IV Vulvar Cancer AJCC v8
- Stage IV Ovarian Cancer AJCC v8
- Stage IVA Cervical Cancer AJCC v8
- Stage IVA Lung Cancer AJCC v8
- Stage IVA Ovarian Cancer AJCC v8
- Stage IVA Vulvar Cancer AJCC v8
- Stage IVB Cervical Cancer AJCC v8
- Stage IVB Lung Cancer AJCC v8
- Stage IVB Ovarian Cancer AJCC v8
- Stage IVB Vulvar Cancer AJCC v8
- Vulva Squamous Cell Carcinoma
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 11, 2019 (Actual)
- Primary completion
- May 2027 (Estimated)
- Completion
- May 2027 (Estimated)
- Last update posted
- Aug 13, 2026
2019 – 2027
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Wake Forest Baptist Comprehensive Cancer Center | Winston-Salem | North Carolina | 27157 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03987555, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 13, 2026 · Synced Oct 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03987555 live on ClinicalTrials.gov.